Pasar al contenido principal

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Conexión rápida

Nota informativa

A closer look on how Dr. Reddy's met the stringent regulatory requirement of genotoxic impurities in Ranolazine

Genotoxic impurities (GTIs) have recently challenged the pharmaceutical industry by virtue of their presence at a level of parts per million (ppm) in drug products, especially in high dosage molecules like Ranolazine, which has a prescribed maximum daily dosage (MDD) of 2000 mg.

In this whitepaper, we talk about steps taken by Dr. Reddy's during the product development phase to address this challenge by designing the process in such a way that all these PGIs / GTI’s are within the control in the manufacturing approach followed by Dr. Reddy’s for Ranolazine.

Read our latest whitepaper on this topic by filling the contact form below.

You can also explore our Ranolazine API offering by clicking on the link below:

Explore other Whitepapers:

Know More

Download Now

Complete el formulario de contacto a continuación para ver el documento técnico

Nuestra lienea de contacto email: | +91 40 49002253

Meet with our product experts in one-on-one virtual sessions

Our experts will answer your questions, provide advice, and help you understand our product better

Set Up a Meeting

Active Pharmaceutical Ingredients

API Supplier of the Year

Global Generics & Biosimilars Awards 2021 winner for 3 consecutive years!

Explore our Products